87014-71-9

Upstream product

• 50-00-0 formaldehyd 
• 31775-67-4 (±)-trans-2-aminocyclopentanol hydrochloride 

Downstream Products

• 68327-09-3 (+/-)-trans-2-Dimethylaminocyclopentylacetat-methiodid 
• 67440-68-0 trans-N,N-dimethyl-N'-<4-(trifluoromethyl)phenyl>-1,2-cyclopentanediamine 
• 67440-41-9 (1S,2S)-N,N-Dimethyl-N'-p-tolyl-cyclopentane-1,2-diamine 
• 67440-50-0 (1S,2S)-N-(4-Methoxy-phenyl)-N',N'-dimethyl-cyclopentane-1,2-diamine 
• 67450-63-9 N-(3-Chloro-4-fluoro-phenyl)-N-((1R,2R)-2-dimethylamino-cyclopentyl)-propionamide 
• 67450-65-1 N-(3,4-Dibromo-phenyl)-N-((1R,2R)-2-dimethylamino-cyclopentyl)-propionamide 
• 67440-70-4 (1S,2S)-N-(3-Chloro-4-methyl-phenyl)-N',N'-dimethyl-cyclopentane-1,2-diamine 
• 67440-72-6 (1S,2S)-N-(4-Chloro-3-methyl-phenyl)-N',N'-dimethyl-cyclopentane-1,2-diamine 
• 167280-11-7 nitrile of 2-(N,N-dimethylamino)cyclopentanecarboxylic acid 
• 67440-36-2 (1S,2S)-N,N-Dimethyl-N'-phenyl-cyclopentane-1,2-diamine 
• 67440-39-5 (1S,2S)-N,N-Dimethyl-N'-m-tolyl-cyclopentane-1,2-diamine 
• 67440-37-3 (1S,2S)-N,N-Dimethyl-N'-o-tolyl-cyclopentane-1,2-diamine 
• 67440-52-2 (1S,2S)-N-(3-Fluoro-phenyl)-N',N'-dimethyl-cyclopentane-1,2-diamine 
• 67440-45-3 (1S,2S)-N-(3-Chloro-phenyl)-N',N'-dimethyl-cyclopentane-1,2-diamine 

Relevant academic research and scientific papers

Cycloalkyl and heterocycloalkyl inhibitors as well as preparation method and application thereof

The invention relates to cycloalkyl and heterocycloalkyl inhibitors as well as a preparation method and application thereof. Specifically, the compounds disclosed by the invention have a structure as shown in a formula (I). The invention also discloses a preparation method of the compounds and application of the compounds as KRASG12C inhibitors. The compounds have a good selective inhibition effect on KRASG12C, and have better pharmacodynamic and pharmacokinetic properties and lower toxic and side effects.

1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.